Table 2.
Effects of acute intralipid and combination of intralipid plus insulin administration on circulating lipids, endocrine FGFs, and fetuin- in control (n = 10) and PCOS (n = 11) subjects.
| Control | One-way | post-hoc | PCOS | One-way | post-hoc | Two-way | ||
|---|---|---|---|---|---|---|---|---|
| (N = 10) | ANOVA | analysis | (N = 11) | ANOVA | analysis | RM ANOVA | ||
| Infusion (min) | Mean ± SD | p | p | Mean ± SD | p | p | p | |
| FGF19 (pg/ml) | Baseline (0) | 129.5 ± 94.3 | ** | 84.67 ± 58.4 | *** | NS | ||
| Lipid (60) | 65.08 ± 36.0 | # | 33.4 ± 15.8 | ### | ||||
| Lipid (180) | 53.1 ± 37.3 | ## | 35.73 ± 18.9 | ### | ||||
| Lipid + Ins (240) | 44.07 ± 24.7 | ## | 41.15 ± 19.8 | ## | ||||
| Lipid + Ins (300) | 57.10 ± 19.5 | # | 45.79 ± 19.9 | ## | ||||
| FGF21 (pg/ml) | Baseline (0) | 163.00 ± 102.0 | *** | 143.60 ± 124.6 | *** | $ | ||
| Lipid (60) | 114.50 ± 91.2 | 138.20 ± 174.6 | ||||||
| Lipid (180) | 231.00 ± 164.8 | ### | 309.10 ± 174.8 | ### | ||||
| Lipid + Ins (240) | 403.00 ± 275.7 | ### | 600.90 ± 339.6 | ### | ||||
| Lipid + Ins (300) | 959.00 ± 618.3 | ### | 1056.00 ± 386.5 | ### | ||||
| FGF23 (pg/ml) | Baseline (0) | 139.00 ± 45.3 | ** | 138.20 ± 62.9 | NS | NS | ||
| Lipid (60) | 105.00 ± 47.2 | 136.40 ± 62.49 | ||||||
| Lipid (180) | 103.00 ± 55.8 | 123.60 ± 58.01 | ||||||
| Lipid + Ins (240) | 85.00 ± 26.7 | ## | 120.00 ± 59.8 | |||||
| Lipid + Ins (300) | 116.00 ± 57.4 | 159.10 ±109.2 | ||||||
| Fetuin-A (μg/ml) | Baseline (0) | 0.68 ± 0.2 | NS | 0.82 ± 0.2 | NS | NS | ||
| Lipid (60) | 0.74 ± 0.2 | 0.84 ± 0.2 | ||||||
| Lipid (180) | 0.71 ± 0.1 | 0.78 ± 0.2 | ||||||
| Lipid + Ins (240) | 0.68 ± 0.1 | 0.80 ± 0.2 | ||||||
| Lipid + Ins (300) | 0.72 ± 0.1 | 0.81 ± 0.2 | ||||||
| M-value | 2.4 ± 1.7 | 1.2 ± 0.8 |
One-way ANOVA group analysis was performed in controls to determine significant differences between time points for FGF19, 21, 23 and fetuin-A within control group
***p < 0.0001;
**p < 0.001. post hoc analysis with Bonferroni correction for subgroup analysis comparing each the time point with control baseline expression
###p < 0.0001;
##p < 0.001;
#p < 0.05. Similarly, One-way ANOVA group analysis was performed in PCOS women separately
*** p < 0.0001;
**p < 0.001, with the post hoc analysis undertaken to compare each time point measurements within the PCOS group to baseline expression levels in the PCOS group ###p < 0.0001; ##p < 0.001. Two-way RM ANOVA analysis was performed to compare between control and PCOS group; $p < 0.05. FGF19, fibroblast growth factor 19; FGF21, fibroblast growth factor 21; FGF23, fibroblast growth factor 23; M-value, Insulin sensitivity index; NS, non-significant.